José Vicente Pons Andreu

FORESTCHEMICAL GROUP, S.A. is a chemical company, with significant research in the field of nanotechnology, biotechnology and industrial adhesives Forest Chemical Group, SL has specialized in manufacturing and selling of hot melt adhesive with the latest technologies, offering the most advanced products with the highest guarantee of quality. Responsibility in R&D is one of the pillars of the company, reflected in joint agreements with universities and technological institutes having the objective of securing the continuous improvement of its processes and products.

Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.

COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A es una sociedad gestora de inversión española inscrita en el Registro de Sociedades Gestoras de Entidades de Inversión de tipo Cerrado (SGEIC) de la CNMV con el número 107. Su sede está en calle José Abascal nº 58, 7º Derecha, 28003 Madrid. Nuestro objetivo es que el fondo Columbus Innvierte Life Science, genere altos rendimientos gracias a una cartera selectiva de inversiones en etapa semilla en empresas privadas establecidas dentro del sector sanitario y de ciencias de la vida. Ponemos a su disposición un equipo de inversión sólido, con experiencia a nivel internacional y con una amplia trayectoria en la búsqueda de la excelencia innovadora que proviene de las instituciones académicas españolas. COLUMBUS VENTURE PARTNERS, S.G.E.I.C., S.A proporciona experiencia probada en la creación y la financiación de empresas para acelerar la comercialización y, además, concede a las empresas de su cartera acceso rápido al ecosistema de I+D en el ámbito biotecnológico/farmacéutico de capital de riesgo dinámico del Reino Unido y Boston/Cambridge.

Dextro es una compañía dedicada a la gestión hospitalaria. Ponemos a disposición de los servicios médicos y de la farmacia de los hospitales, soluciones que mejoran la atención al paciente y el flujo de trabajo asistencial, con el objetivo de optimizar los recursos para mejorar los resultados. En Dextro ofrecemos soluciones diseñadas a medida para hospitales y unidades médicas que desean dar un paso más en sus procesos, facilitando la toma de decisiones y disminuyendo los fallos asistenciales. Tenemos amplia experiencia en reducción de listas de espera e implantación de protocolos que aceleran la recuperación del paciente. Somos el partner que buscan los hospitales que valoran la mejora continua y persiguen la excelencia asistencial.

FORESTCHEMICAL GROUP, S.A. is a chemical company, with significant research in the field of nanotechnology, biotechnology and industrial adhesives Forest Chemical Group, SL has specialized in manufacturing and selling of hot melt adhesive with the latest technologies, offering the most advanced products with the highest guarantee of quality. Responsibility in R&D is one of the pillars of the company, reflected in joint agreements with universities and technological institutes having the objective of securing the continuous improvement of its processes and products.

BioSequence ofrece servicios de ayuda para el diagnóstico oncológico personalizado. Utilizamos tecnologías genómicas como la ultrasecuenciación y los microarrays para detectar mutaciones en genes relacionados con la mayor parte de los cánceres y tratamientos oncológicos conocidos. Trabajamos en colaboración con el Baylor College of Medicine’s Cancer Genetics Laboratory (CGL) para ofrecer servicios de máxima calidad y rigor científico.

Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.